-
Dec 11, 2024 | 
openlegalblogarchive.org | Erin Estey Hertzog
Skip to content
-
Nov 8, 2024 | 
jdsupra.com | Erin Estey Hertzog |Ross Margulies
This overview is excerpted from Manatt on Health, Manatt’s subscription service that provides in-depth insights and analysis focused on the legal, policy and market developments.
-
Oct 16, 2024 | 
jdsupra.com | Patrick Brennan |Erin Estey Hertzog |Ross Margulies
This overview is excerpted from Manatt on Health, Manatt’s subscription service that provides in-depth insights and analysis focused on the legal, policy and market developments.
-
Feb 15, 2024 | 
mondaq.com | Ross Margulies |Erin Estey Hertzog
On February 2, 2024, the “gang of six”—a
bipartisan group of six senators who have traditionally championed
reforms to the 340B program1 —introduced a
discussion draft of a bill that would modify the program that
provides safety net providers with access to low-cost medications
from participating manufacturers. The 340B statute has not been
modified since 2010.
-
Feb 9, 2024 | 
jdsupra.com | Erin Estey Hertzog |Ross Margulies
On February 2, 2024, the “gang of six”—a bipartisan group of six senators who have traditionally championed reforms to the 340B program1 —introduced a discussion draft of a bill that would modify the program that provides safety net providers with access to low-cost medications from participating manufacturers. The 340B statute has not been modified since 2010.
-
Feb 7, 2024 | 
mondaq.com | Erin Estey Hertzog |Ross Margulies
The Centers for Medicare & Medicaid Services (CMS) issued a
request for information (RFI) seeking data-related input from the
public to improve transparency in the fast-growing Medicare
Advantage (MA) market.
CMS is soliciting input on data that could improve transparency
in all aspects of the MA program, including access to care, prior
authorization, supplemental benefits, and provider networks.
Comments are due May 29, 2024.
-
Feb 1, 2024 | 
jdsupra.com | Erin Estey Hertzog |Alexander Somodevilla
Key Takeaways: On January 30, 2024, the Center for Medicare and Medicaid Innovation (CMMI) issued additional details regarding the forthcoming Cell and Gene Therapy (CGT) Access Model, which was initially announced in February 2023. The model will test whether a CMS-led approach to negotiating and administering outcomes-based arrangements (OBAs) for CGTs will improve access and health outcomes for Medicaid beneficiaries and reduce health care costs.
-
Jan 31, 2024 | 
jdsupra.com | Erin Estey Hertzog |Ross Margulies
Key Takeaways: The Centers for Medicare & Medicaid Services (CMS) issued a request for information (RFI) seeking data-related input from the public to improve transparency in the fast-growing Medicare Advantage (MA) market. CMS is soliciting input on data that could improve transparency in all aspects of the MA program, including access to care, prior authorization, supplemental benefits, and provider networks. Comments are due May 29, 2024.
-
Dec 11, 2023 | 
jdsupra.com | Thomas Barker |Brian Carey |Erin Estey Hertzog
Key Takeaways: The draft framework represents the most significant formal step taken by any Administration toward the exercise of march-in rights over patents of inventions made with federally funded research since the enactment of the Bayh-Dole Act in 1980.
-
Nov 8, 2023 | 
jdsupra.com | Haider Andazola |Thomas Barker |Erin Estey Hertzog
Key Takeaways: On November 3, 2023, a Federal District Court issued a decision invalidating the Health Resources and Services Administration’s (HRSA’s) 340B “patient” definition.
